3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
22
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Prostate Adenocarcinoma
2
Neoplasm Metastasis
2
Stage I Prostate Adenocarcinoma AJCC v7
1
Salivary Gland Neoplasms
1
Primary Dysautonomias
1
Paget Disease, Extramammary
1
PSA Level Greater Than Two
1
Non-Muscle Invasive Bladder Urothelial Carcinoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Kidney Diseases
1
Hypertension
1
Glioma
1
Glioblastoma
1
Carcinoma, Renal Cell
1
Bulbo-Spinal Atrophy, X-Linked
1
Interventions
Oxaliplatin
19
pembrolizumab
13
Fluorouracil
12
Leucovorin
11
Capecitabine
11
Paclitaxel
10
Gemcitabine
8
Docetaxel
8
zolbetuximab
6
cemiplimab
6
Cisplatin
6
Albumin-Bound Paclitaxel
6
durvalumab
5
Ramucirumab
5
Radiotherapy
5
Irinotecan
4
Cyclophosphamide
4
130-nm albumin-bound paclitaxel
4
trastuzumab deruxtecan
3
tislelizumab
3
lenvatinib
3
enzalutamide
3
darolutamide
3
Trastuzumab
3
Taxes
3
S 1 (combination)
3
Radiosurgery
3
Pemetrexed
3
Nivolumab
3
Carboplatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
bicalutamide
×
1 year
×
Clear all
No trials found.